

---

**THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

---

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in TYK Medicines, Inc (浙江同源康醫藥股份有限公司), you should at once hand this circular and the accompanying form(s) of proxy to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

---



**TYK Medicines, Inc**  
**浙江同源康醫藥股份有限公司**  
*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2410)**

**(1) GENERAL MANDATE TO ISSUE SHARES; AND**  
**(2) NOTICE OF THE FIRST EXTRAORDINARY**  
**GENERAL MEETING OF 2026**

---

Capitalized terms used in this cover page shall have the same meanings as defined in this circular. A letter from the Board is set out on pages 3 to 7 of this circular.

The Company will convene and hold the EGM on 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC at 2:00 p.m. on Wednesday, July 15, 2026. The notice of the EGM is set out on pages EGM-1 to EGM-2 of this circular. The proxy form for use at the EGM is enclosed herein, which was also published on the websites of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.tykmedicines.com](http://www.tykmedicines.com)).

Whether or not you intend to attend and/or vote at the EGM in person, you are requested to complete the proxy form in accordance with the instructions printed thereon and return the proxy form to the H Share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible and in any event, not later than 24 hours before the time appointed for holding the EGM (i.e. 2:00 p.m. on Tuesday, July 14, 2026) or any adjournment thereof (as the case may be). Completion and return of the proxy form will not preclude you from attending and voting in person at the EGM or any adjournment thereof (as the case may be) should you so wish, and in this case, the proxy form should be deemed to be revoked.

Reference to times and dates in this circular are to Hong Kong local times and dates.

June 29, 2026

---

## TABLE OF CONTENTS

---

<b>DEFINITIONS</b> .....	1
<b>LETTER FROM THE BOARD</b> .....	3
<b>NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026</b> .....	EGM-1

---

## DEFINITIONS

---

*In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:*

<b>“Articles of Association”</b>	the articles of association of the Company, as amended from time to time
<b>“Board” or “Board of Directors”</b>	the board of Directors
<b>“China” or the “PRC”</b>	the People’s Republic of China, for the purpose of this circular only, excluding Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan, except where the context requires otherwise
<b>“Company”, “we”, “us”, or “our”</b>	TYK Medicines, Inc (浙江同源康醫藥股份有限公司), a joint stock company incorporated in the PRC with limited liability on November 2, 2017
<b>“Director(s)”</b>	the director(s) of the Company
<b>“EGM”</b>	the first extraordinary general meeting of 2026 of the Company to be convened on 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC at 2:00 p.m. on Wednesday, July 15, 2026 or any adjournment thereof
<b>“H Share(s)”</b>	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong Dollars and listed on the Stock Exchange
<b>“Hong Kong”</b>	the Hong Kong Special Administrative Region of the PRC
<b>“Issue Mandate”</b>	the general and unconditional mandate proposed to be granted to the Board at the EGM to allot, issue and/or deal with additional H Shares (including any sale or transfer of the treasury shares out of treasury) up to 20% of the total number of issued Shares (excluding the treasury shares, if any) as of the date of passing of the relevant resolution approving such mandate, as further detailed under the paragraphs headed “General Mandate to Issue Shares” in this circular
<b>“Listing Rules”</b>	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time

---

## DEFINITIONS

---

<b>“RMB”</b>	Renminbi, the lawful currency of the PRC
<b>“Share(s)”</b>	shares of the Company
<b>“Shareholder(s)”</b>	holder(s) of the Share(s)
<b>“Stock Exchange”</b>	The Stock Exchange of Hong Kong Limited
<b>“treasury shares”</b>	H Shares bought back and held in treasury by the Company, which has the meaning ascribed to it under the Hong Kong Listing Rules
<b>“%”</b>	per cent

---

LETTER FROM THE BOARD

---



**TYK Medicines, Inc**  
**浙江同源康醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2410)**

**Executive Director:**

Dr. WU Yusheng (吳豫生)  
*(Chairman of the Board and Chief Executive Officer)*

**Non-executive Directors:**

Dr. LI Jun (李鈞)  
Dr. GU Eric Hong (顧虹)  
Dr. JIANG Mingyu (蔣鳴昱)  
Mr. HE Chao (何超)  
Dr. ZHU Xiangyang (朱向陽)

**Independent Non-executive Directors:**

Dr. LENG Yuting (冷瑜婷)  
Dr. XU Wenqing (許文青)  
Dr. SHEN Xiuhua (沈秀華)  
Mr. JIANG Xiaolin (江曉林)

**Registered Office and Headquarter:**

Room 1403-2, Floor 14, Tower A  
Changxing World Trade Building  
No. 1278 Mingzhu Road  
Changxing Economic Development Zone  
Huzhou  
Zhejiang Province  
PRC

**Principal Place of Business in the PRC:**

8th Floor, Building T2  
China Eastern Binjiang Center  
No. 277 Longlan Road  
Xuhui District  
Shanghai  
PRC

**Principal Place of Business in Hong Kong:**

Room 1901, 19/F, Lee Garden One  
33 Hysan Avenue  
Causeway Bay  
Hong Kong

June 29, 2026

*To the Shareholders*

Dear Sir/Madam,

**(1) GENERAL MANDATE TO ISSUE SHARES; AND  
(2) NOTICE OF THE FIRST EXTRAORDINARY  
GENERAL MEETING OF 2026**

---

## LETTER FROM THE BOARD

---

### I. INTRODUCTION

The purpose of this circular is to provide you with information regarding the resolution to be proposed at the EGM to be held on Wednesday, July 15, 2026, to enable you to make an informed decision on whether to vote for or against the proposed resolution at the EGM. For details of the resolution to be proposed at the EGM, please refer to the notice of the EGM.

At the EGM, a special resolution will be proposed to consider and, if thought fit, approve the following matter:

- (1) General mandate to issue Shares pursuant to the Issue Mandate.

### II. MATTER TO BE CONSIDERED AT THE EGM

#### SPECIAL RESOLUTION

##### *(1) General Mandate to Issue Shares*

To enable the Company to issue shares in a timely and flexible manner in accordance with market conditions and the Company's operational development needs, and to further optimize the Company's capital structure and financial soundness, the Company will propose a special resolution at the EGM to consider and approve the grant of a general mandate to the Board to allot and issue (including the sale and transfer of any treasury shares) new H Shares not exceeding 20% of the total issued Shares as at the date of the resolution (excluding treasury shares, if any), and in the event that the Company has repurchased Shares previously, the number of such repurchased Shares may be added to the number of new Shares to be issued. This mandate is in the interests of the Company as it provides added flexibility, enabling the Company to promptly react to market opportunities, and to take advantage of favorable market conditions when such window of opportunities arises.

Such mandate shall include but not be limited to the following matters:

- (a) the terms and conditions of allotment, issuance, and disposal;
- (b) in the case of a placement or public offering of Shares for cash consideration, the Company shall not issue any Shares under the general mandate if the relevant price represents a discount of 20% or more to the benchmark price of the Shares as defined under Rule 13.36 of the Listing Rules;
- (c) to authorize the Board and permit the Board to further authorize the chairperson and its authorized persons to obtain approvals from all relevant governmental and/or regulatory authorities (where applicable) for the exercise of the general mandate in accordance with applicable laws;

---

## LETTER FROM THE BOARD

---

- (d) to authorize the Board and permit the Board to authorize the chairperson and its authorized persons to approve, execute, amend, and take or procure to take all such necessary documents, deeds and actions as they deem appropriate in connection with the allotment, issuance and disposal of any new Shares under the general mandate, complete the necessary procedures, and take other necessary actions;
- (e) to authorize the Board and permit the Board to further authorize the chairperson and its authorized persons to handle matters related to the allotment, issuance and disposal of such Shares within the validity period upon obtaining approvals, consents, or registration confirmations from regulatory authorities; and
- (f) to authorize the Board and permit the Board to authorize the chairperson and its authorized persons to increase the registered capital of the Company upon completion of the allotment and issuance in accordance with the details of such allotment and issuance and the Company's shareholding structure, and to make appropriate and necessary amendments to the Articles of Association.

Once approved, the general mandate shall take effect upon the passing of the relevant resolution at the EGM and shall terminate until the earliest of the following dates: (a) the date falling 12 months after the date of approval of the EGM of the Company; (b) the conclusion of the 2026 annual general meeting of the Company; and (c) the date on which the Shareholders, by way of a special resolution passed in a general meeting, revoke or vary the resolution approving the general mandate.

### III. THE EGM

The notice convening the EGM on 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC on Wednesday, July 15, 2026 at 2:00 p.m. is set out on pages EGM-1 to EGM-2 in this circular. In order to determine the holders of H Shares who are entitled to attend and vote at the forthcoming EGM, the H Share register of members of the Company will be closed from Friday, July 10, 2026 to Wednesday, July 15, 2026 (both dates inclusive), during which no H Share transfer will be registered. To be eligible to attend the EGM and vote, all completed transfer documents (accompanied by the relevant share certificates) must be submitted to the Company's H Share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, for registration before 4:30 p.m. on Thursday, July 9, 2026. Pursuant to Rule 17.05A of the Listing Rules, the trustee holding unvested shares of a share scheme, whether directly or indirectly, shall abstain from voting on matters that require Shareholders' approval under the Listing Rules, unless otherwise required by law to vote in accordance with the beneficial owner's direction and such a direction is given. The trustee of the Company's share incentive scheme shall not exercise the voting rights attached to 1,480,500 Shares held by it. The record date for determining the Shareholders' eligibility to attend and vote at the EGM is Wednesday, July 15, 2026.

The proxy form for use at the EGM is enclosed in this circular and published on the websites of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.tykmedicines.com](http://www.tykmedicines.com)).

---

## LETTER FROM THE BOARD

---

If you intend to attend the EGM by proxy, you are required to return the duly completed accompanying proxy form according to the instructions printed thereon. Shareholders who intend to attend the EGM by proxy are required to duly complete the proxy form and return the same to Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong as soon as practicable but in any event not less than 24 hours before the time appointed for holding the EGM (i.e. 2:00 p.m. Tuesday, July 14, 2026), or any adjourned meeting thereof (as the case may be). Completion and return of the proxy form will not preclude you from attending and voting in person at the EGM.

### **IV. VOTING BY POLL**

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of Shareholders at a general meeting must be taken by poll except for purely procedural or administrative matters. The chairman of the EGM shall therefore demand that voting on the resolution set out in the notice of the EGM be taken by way of poll pursuant to the existing Articles of Association.

### **V. RESPONSIBILITY STATEMENT**

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this supplementary circular misleading.

### **VI. RECOMMENDATION**

The Directors consider that the proposed resolution is in the interests of the Company and the Shareholders as a whole. As such, the Directors recommend the Shareholders to vote in favour of the resolution set forth in the notice.

---

## LETTER FROM THE BOARD

---

### VII. MISCELLANEOUS

Unless otherwise provided herein, the English text of this circular shall prevail over the Chinese text for the purpose of interpretation.

By order of the Board  
**TYK Medicines, Inc**  
(浙江同源康醫藥股份有限公司)  
**Dr. WU Yusheng**  
*Chairman, Executive Director and  
Chief Executive Officer*

---

## NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026

---

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



**TYK Medicines, Inc**  
**浙江同源康醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2410)**

## NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026

NOTICE IS HEREBY GIVEN THAT the first extraordinary general meeting of 2026 (the “EGM”) of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “Company”) will be held at 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC at 2:00 p.m. on Wednesday, July 15, 2026 for the purpose of considering and, if though fit, passing the following resolution. Unless otherwise required, capitalized terms used in this notice shall have the same meanings as those defined in the circular of the Company dated June 29, 2026.

### SPECIAL RESOLUTION

1. To consider and approve the Issue Mandate to issue Shares.

By Order of the Board  
**TYK Medicines, Inc**  
(浙江同源康醫藥股份有限公司)  
**Dr. WU Yusheng**  
*Chairman, Executive Director and  
Chief Executive Officer*

Hong Kong

June 29, 2026

---

## NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026

---

*Notes:*

1. The resolution at the EGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Listing Rules. The results of the poll will be published on the websites of the Company at [www.tykmedicines.com](http://www.tykmedicines.com) and the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) after the EGM.
2. Any shareholder entitled to attend and vote at the EGM convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a shareholder of the Company. If a shareholder of the Company appoints more than one proxy, such proxies shall only exercise their voting rights by a poll. For the avoidance of doubt, holders of treasury shares (if any) shall abstain from voting on the relevant treasury shares at the EGM in accordance with the requirements of the Listing Rules.
3. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the H share registrar of the Company, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, at least 24 hours before the EGM (i.e. before 2:00 p.m. on Tuesday, July 14, 2026) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a shareholder from attending and voting in person at the EGM or any adjourned meeting thereof should he/she so wish.
4. For the purpose of determining the holders of H Shares who are entitled to attend and vote at the forthcoming EGM, the H Share register of members of the Company will be closed from Friday, July 10, 2026 to Wednesday, July 15, 2026 (both dates inclusive), during which, no transfer of H Shares will be registered. In order to be eligible to attend and vote at the EGM, all completed transfer documents (which shall be accompanied by the relevant share certificates) must be lodged with the H Share registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong no later than 4:30 p.m. on Thursday, July 9, 2026 for registration. Pursuant to Rule 17.05A of the Listing Rules, the trustee holding unvested shares of a share scheme, whether directly or indirectly, shall abstain from voting on matters that require Shareholders' approval under the Listing Rules, unless otherwise required by law to vote in accordance with the beneficial owner's direction and such a direction is given. The trustee of the Company's share incentive scheme shall not exercise the voting rights attached to 1,480,500 Shares held by it. The record date for determining the Shareholders' eligibility to attend and vote at the EGM is Wednesday, July 15, 2026.
5. Where there are joint registered holders of any share, any one of such joint holders may vote, either in person or by proxy, in respect of such shares as if he/she was solely entitled thereto, but if more than one of such joint holders are present at the EGM, whether in person or by proxy, the joint registered holder present whose name stands first on the register of members of the Company in respect of the shares shall alone be entitled to vote in respect thereof.
6. A shareholder or his/her/its proxy should produce proof of identity when attending the EGM.
7. The EGM is expected to last for no more than half a business day. Shareholders and proxies attending the meeting shall be responsible for their own travel and accommodation expenses.
8. Shareholders may contact the Company at [yiting.huang@tykmedicines.com](mailto:yiting.huang@tykmedicines.com) or [chenchen.tong@tykmedicines.com](mailto:chenchen.tong@tykmedicines.com) for any enquiries in respect of the EGM.

*As at the date of this notice, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.*